EIKN Overview

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.

Wall Street analysts forecast EIKN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EIKN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Eikon Therapeutics Inc revenue for the last quarter amounts to -83.17M USD, increased 22.71

Eikon Therapeutics Inc. EPS for the last quarter amounts to -41790000.00 USD, decreased -33.94

Eikon Therapeutics Inc (EIKN) has 384 emplpoyees as of April 20 2026.

Today EIKN has the market capitalization of 644.25M USD.